Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1/2 2Phase NA 1Phase EARLY_PHASE1 1Phase 3 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1Other 1Lymphoid 1

Conditions

Neurotoxicity Syndromes 1Mucositis 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Hematologic Neoplasms 1

Interventions

pembrolizumab 410Cyclophosphamide 394Carboplatin 306Gemcitabine 286Nivolumab 276Paclitaxel 274Cisplatin 252Radiotherapy 225Dexamethasone 210Bevacizumab 209fludarabine 192Docetaxel 187Rituximab 183Capecitabine 171Oxaliplatin 158Lenalidomide 157Fluorouracil 152Temozolomide 138Cytarabine 135Etoposide 128Irinotecan 124Cetuximab 123fludarabine phosphate 120Injections 118venetoclax 116Ipilimumab 115Doxorubicin 114Azacitidine 108130-nm albumin-bound paclitaxel 108Pemetrexed 107

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Interventional × glucarpidase × Clear all
NCT00727831 2014-01-27

Methotrexate, Glucarpidase, and Leucovorin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma

University College, London

Phase 1/2 Completed
4 enrolled
LymphoidOther

Lymphoma, Lymphoma, Large B-Cell, Diffuse, Neurotoxicity Syndromes, Mucositis

NCT00424645 2012-12-06

Voraxaze for Delayed Methotrexate Clearance

M.D. Anderson Cancer Center

Phase 1/2 Terminated
3 enrolled 2 charts
Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡